Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 3Melanoma 2Lung Neoplasms 2Neoplasms 1Kidney Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × AZD 6244 × Breast × Clear all
NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

OHSU Knight Cancer Institute

Phase 2 Terminated
24 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT02583542 2020-02-25

TORCMEK

Queen Mary University of London

Phase 1/2 Unknown
118 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Russian Academy of Medical Sciences

Phase 2 Unknown
164 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡